What's New at Charles River
   
 
 
   
   

In Vitro Models for Nail (Ungual) Absorption Offered by Charles River

January 19, 2011 - As part of our commitment to reduce, refine and replace the use of animals in research, an in vitro model for assessing transungual drug delivery has been added to our portfolio of tests to help accelerate the development of compounds.

Onchomycosis (fungal nail infection) affects about 6-8% of the adult population. Historically, many topically applied onycomychotic drug formulations have had limited success due to poor transungual drug delivery. As a result, we offer this new in vitro model to provide key information regarding formulation selection and optimization to improve the effectiveness of drug delivery.

Our in vitro model utilizes human cadaver nails mounted in flow-through diffusion cells. Following topical application of the onycomychotic drug formulation at a clinically relevant exposure level, the receptor medium is collected to gain an absorption profile for any drug that passes through the nail and reached the nail bed. After absorption monitoring, the nail is sectioned longitudinally to provide distribution and kinetic information of the drug within the nail plate.

For more information about these assays, see our technical sheet or contact us at askcharlesriver@crl.com.

   
Discover the full range of Charles River Products and Services
The Source

For more information, contact us at:

1.877.CRIVER.1 (1.877.274.8371)
askcharlesriver@crl.com

view all

News & Events

view all
May 14 - New Models for Evaluating COPD or ...
May 11 - Expert Safety Testing to Accelerat...
Jun 17-Jun 20 -  Noordwijk aan Zee, the Netherlands - 19th MDO Meeting / 12th European ...
Jun 02-Jun 05 - Vancouver, British Columbia - CALAS
Jun 05-Jun 05 - King of Prussia, Pennsylvania - Assessment of Immunomodulation for Biol...
Jun 05-Jun 08 - Saint Germain sur l’Arbresle, France - Charles River LAL Seminar Series
view all
Scientist I Wilmington, MA
Manager International Tax Wilmington, MA

Charles River Laboratories, Inc.